Your browser doesn't support javascript.
loading
An Injectable Hydrogel for Enhanced FeGA-Based Chemodynamic Therapy by Increasing Intracellular Acidity.
Zeng, Wen; Jiang, Dazhen; Liu, Zeming; Suo, Weilong; Wang, Ziqi; Zhu, Daoming; Huang, Qinqin.
Afiliação
  • Zeng W; Department of Molecular Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Jiang D; Department of Ophthalmology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Liu Z; Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Suo W; Department of Plastic and Cosmetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang Z; Department of Molecular Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Zhu D; Key Laboratory of Artificial Micro- and Nano-Structures of Ministry of Education, School of Physics and Technology, Wuhan University, Wuhan, China.
  • Huang Q; Department of Molecular Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Oncol ; 11: 750855, 2021.
Article em En | MEDLINE | ID: mdl-34631588
ABSTRACT
Hydroxyl radical (•OH)-mediated chemodynamic therapy (CDT) is an emerging antitumor strategy, however, acid deficiency in the tumor microenvironment (TME) hampers its efficacy. In this study, a new injectable hydrogel was developed as an acid-enhanced CDT system (AES) for improving tumor therapy. The AES contains iron-gallic acid nanoparticles (FeGA) and α-cyano-4-hydroxycinnamic acid (α-CHCA). FeGA converts near-infrared laser into heat, which results in agarose degradation and consequent α-CHCA release. Then, as a monocarboxylic acid transporter inhibitor, α-CHCA can raise the acidity in TME, thus contributing to an increase in ·OH-production in FeGA-based CDT. This approach was found effective for killing tumor cells both in vitro and in vivo, demonstrating good therapeutic efficacy. In vivo investigations also revealed that AES had outstanding biocompatibility and stability. This is the first study to improve FeGA-based CDT by increasing intracellular acidity. The AES system developed here opens new opportunities for effective tumor treatment.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article